Holen Sie sich die Stockscreener-App
11.71
14.96%
-2.06
Handel nachbörslich:
11.50
-0.21
-1.79%
Schlusskurs vom Vortag:
$13.77
Offen:
$12.98
24-Stunden-Volumen:
785.49K
Relative Volume:
1.68
Marktkapitalisierung:
$356.76M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.05M
KGV:
-2.2827
EPS:
-5.13
Netto-Cashflow:
$-146.15M
1W Leistung:
-22.09%
1M Leistung:
-32.08%
6M Leistung:
-24.89%
1J Leistung:
+0.34%
1-Tages-Spanne:
$11.57
$13.09
1-Wochen-Bereich:
$11.57
$15.11
52-Wochen-Spanne:
$9.12
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
Firmenname
Keros Therapeutics Inc
Sektor
Branche
Telefon
617-314-6297
Adresse
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
11.71 | 419.52M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-01-21 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-12-16 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-16 | Bestätigt | Oppenheimer | Outperform |
| 2024-12-13 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-12 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-12-12 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Eingeleitet | Jefferies | Buy |
| 2024-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-23 | Eingeleitet | Guggenheim | Buy |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-21 | Eingeleitet | William Blair | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-07-31 | Eingeleitet | Wedbush | Outperform |
| 2023-07-26 | Eingeleitet | BofA Securities | Buy |
| 2023-02-14 | Eingeleitet | Cowen | Outperform |
| 2022-10-18 | Eingeleitet | Truist | Buy |
| 2022-07-26 | Eingeleitet | BTIG Research | Buy |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
Wells Fargo & Company Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $20.00 - MarketBeat
Wells Fargo Maintains "Overweight" on Keros Therapeutics (KROS), Lowers Price Target | KROS Stock News - GuruFocus
Keros Therapeutics Reports FY25 Results, Highlights Progress Across Hematology And Muscle Pipeline - Nasdaq
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates - Bitget
Keros Therapeutics (NASDAQ: KROS) lands $200M Takeda deal and advances TGF-ß pipeline - Stock Titan
Keros Therapeutics (NASDAQ: KROS) swings to 2025 profit on Takeda license windfall - Stock Titan
Keros Highlights Rinvatercept Strategy in Updated Investor Presentation - TipRanks
Keros Therapeutics (NASDAQ:KROS) Posts Earnings Results, Misses Estimates By $0.37 EPS - MarketBeat
Biotech behind new DMD and ALS trials turns 2024 loss into 2025 profit - Stock Titan
KROS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ADAR1 Issues Open Letter to Keros Board, Encouraging Constructive Dialogue on Strategy, Capital Allocation, and Board Renewal - Intellectia AI
Keros Therapeutics Touts Rinvatercept DMD Trial Start, Eyes ALS Phase II Talks at Oppenheimer Conference - Yahoo Finance
Trading the Move, Not the Narrative: (KROS) Edition - Stock Traders Daily
Keros Therapeutics, Inc. (KROS) Investor Outlook: Exploring The 53% Potential Upside - DirectorsTalk Interviews
Keros Therapeutics, Inc. $KROS is Western Standard LLC's Largest Position - MarketBeat
Keros Therapeutics Adds Veteran Finance Leader to Board - TipRanks
Keros Therapeutics adds former Lyell CFO to board - Investing.com
Keros Therapeutics (KROS) CEO awarded 317,000 stock options with vesting hurdles - Stock Titan
Keros Therapeutics (KROS) CFO receives 60,000-share stock option grant - Stock Titan
Keros Therapeutics (KROS) awards Chief Legal Officer 80,000 options - Stock Titan
Keros Therapeutics (NASDAQ: KROS) grants CSO 75,000 options - Stock Titan
Ex-Lyell CFO and healthcare banker Charles Newton joins Keros board - Stock Titan
KROS Technical Analysis & ETF Price Forecast - Intellectia AI
Keros Therapeutics, Inc. (KROS) Investor Outlook: Analyzing a 38.97% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Keros Therapeutics (KROS) CEO auto-sells 7,015 shares for tax withholding - Stock Titan
Can Keros Therapeutics Inc. reach resistance levels soonJuly 2025 Outlook & Verified Swing Trading Watchlists - mfd.ru
Risk Hedge: What is the next catalyst for Keros Therapeutics IncQuarterly Portfolio Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Portfolio Update: Is now the right time to enter Keros Therapeutics IncJuly 2025 Movers & Low Risk Growth Stock Ideas - baoquankhu1.vn
Keros Therapeutics CEO to Present at Multiple Conferences - The Globe and Mail
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - The Manila Times
Keros Therapeutics CEO to Present at Oppenheimer, TD Cowen and Leerink Conferences - TradingView
Keros Therapeutics (NASDAQ: KROS) lines up CEO talks at key conferences - Stock Titan
Sentiment Recap: Can Keros Therapeutics Inc weather a recessionQuarterly Trade Review & Weekly Stock Performance Updates - baoquankhu1.vn
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? - TradingView
Keros Therapeutics (KROS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Tang Capital reports 0% stake in Keros Therapeutics (NASDAQ: KROS) - Stock Titan
D. E. Shaw group discloses 3.9% Keros Therapeutics (KROS) ownership in 13G/A - Stock Titan
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Will Keros Therapeutics Inc. stock keep outperforming rivalsQuarterly Market Review & Community Verified Trade Alerts - mfd.ru
Can Keros Therapeutics Inc. reach all time highs this yearJuly 2025 Analyst Calls & Safe Capital Growth Stock Tips - mfd.ru
Keros Therapeutics, Inc. (KROS) Stock Analysis: Spotlight on a 37.72% Potential Upside in Biotech - DirectorsTalk Interviews
Is Keros Therapeutics Inc. likely to announce a buybackMarket Performance Summary & Free Fast Entry Momentum Trade Alerts - mfd.ru
Why Keros Therapeutics Inc. stock could see breakout soon2025 Market Sentiment & Smart Allocation Stock Tips - mfd.ru
What analyst consensus says on Keros Therapeutics Inc. stockQuarterly Growth Report & Safe Entry Momentum Tips - mfd.ru
How much upside does Keros Therapeutics Inc. haveWeekly Trading Summary & Real-Time Buy Signal Alerts - mfd.ru
Keros Therapeutics: Key Catalysts and Financial Runway in Focus - AD HOC NEWS
Price-Driven Insight from (KROS) for Rule-Based Strategy - Stock Traders Daily
How Keros Therapeutics Inc. stock benefits from global expansion2025 Fundamental Recap & Reliable Entry Point Trade Alerts - mfd.ru
Y Intercept Hong Kong Ltd Lowers Holdings in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics, Inc. $KROS Shares Sold by Federated Hermes Inc. - MarketBeat
Big Picture: What is SIDUs revenue forecastGap Up & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Finanzdaten der Keros Therapeutics Inc-Aktie (KROS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Keros Therapeutics Inc-Aktie (KROS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lerner Lorena Raquel | Chief Science Officer |
Feb 18 '26 |
Sale |
16.35 |
3,873 |
63,324 |
31,127 |
| Cho Esther | SVP, General Counsel |
Feb 18 '26 |
Sale |
16.35 |
4,745 |
77,581 |
39,755 |
| Regnante Keith | CHIEF FINANCIAL OFFICER |
Feb 18 '26 |
Sale |
16.35 |
4,739 |
77,483 |
39,261 |
| Pontifax Management 4 G.P. (20 | 10% Owner |
Oct 15 '25 |
Sale |
17.75 |
4,787,331 |
84,975,125 |
0 |
| ADAR1 Capital Management, LLC | 10% Owner |
Oct 15 '25 |
Sale |
17.75 |
5,389,264 |
95,659,436 |
0 |
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):